Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SH) Latest Company News

Oct 28, 2026, 09:55 UTC
KingMed Diagnostics reported third-quarter 2026 revenue of CNY 1.518 billion, down 1.48% year over year, and net profit of CNY 183 million, up 3,427.94%.
Source:
- finance.sina.cn
Oct 12, 2026, 09:13 UTC
JinYu Medical terminated its planned investment in DRA Company Limited, which had involved subscribing for newly issued shares in three installments totaling RMB 150 million equivalent in Hong Kong dollars.
Source:
- finance.sina.cn
Oct 12, 2026, 09:13 UTC
DRA Company Limited was dissolved after JinYu Medical and DRA's founding shareholders decided to liquidate it and terminate its operations.
Source:
- finance.sina.cn
Oct 10, 2026, 08:07 UTC
Guangzhou Institute of Respiratory Health and KingMed Diagnostics announced the DeepGEM 2.0 multimodal AI model for lung cancer pathology and gene analysis, which can predict 12 lung cancer gene targets in as little as one minute and is expected to reduce testing costs to several hundred yuan.
Source:
- finance.sina.cn
Sep 30, 2026, 09:25 UTC
KingMed Diagnostics completed a share buyback of 7.562 million shares, or 1.63% of total share capital, for a total of 199.97 million yuan at an average price of 26.44 yuan per share, with the shares to be used for equity incentives.
Source:
- finance.sina.cn
- finance.sina.cn
Sep 2, 2026, 07:45 UTC
KingMed Diagnostics established a new wholly-owned subsidiary, Guangzhou Jinkun Medical Laboratory Co., Ltd., with registered capital of 10 million yuan, to engage in medical services and related businesses.
Source:
- finance.sina.cn
Aug 24, 2026, 10:58 UTC
KingMed Diagnostics announced its 2026 first-half results: net profit attributable to shareholders was 190 million yuan, turning from a loss in the same period last year.
Source:
- finance.sina.cn

603882.SH

KingMed Diagnostics reported third-quarter 2026 revenue of CNY 1.518 billion, down 1.48% year over year, and net profit of CNY 183 million, up 3,427.94%.

JinYu Medical terminated its planned investment in DRA Company Limited, which had involved subscribing for newly issued shares in three installments totaling RMB 150 million equivalent in Hong Kong dollars.

DRA Company Limited was dissolved after JinYu Medical and DRA's founding shareholders decided to liquidate it and terminate its operations.

Guangzhou Institute of Respiratory Health and KingMed Diagnostics announced the DeepGEM 2.0 multimodal AI model for lung cancer pathology and gene analysis, which can predict 12 lung cancer gene targets in as little as one minute and is expected to reduce testing costs to several hundred yuan.

KingMed Diagnostics completed a share buyback of 7.562 million shares, or 1.63% of total share capital, for a total of 199.97 million yuan at an average price of 26.44 yuan per share, with the shares to be used for equity incentives.

KingMed Diagnostics established a new wholly-owned subsidiary, Guangzhou Jinkun Medical Laboratory Co., Ltd., with registered capital of 10 million yuan, to engage in medical services and related businesses.

KingMed Diagnostics announced its 2026 first-half results: net profit attributable to shareholders was 190 million yuan, turning from a loss in the same period last year.